To date, only three studies have reported truncating germline mutations in RAD51B: two deleterious mutations were detected among ovarian cancer cases, one splicing mutation in a breast and ovarian cancer family, and one nonsense mutation in a melanoma family [31–33]. This evidence concerns the gene RAD51B and ovarian carcinoma.